CPRC
TMO icon

Consolidated Portfolio Review Corp’s Thermo Fisher Scientific TMO Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-753
Closed -$365K – 370
2025
Q3 		$365K Sell
753
-56
-7% -$26.1K 0.05% 329
2025
Q2 		$328K Buy
809
+126
+18% +$52.7K 0.05% 332
2025
Q1 		$340K Buy
683
+57
+9% +$30.9K 0.05% 284
2024
Q4 		$326K Buy
626
+10
+2% +$5.5K 0.05% 282
2024
Q3 		$381K Buy
616
+29
+5% +$17.2K 0.09% 216
2024
Q2 		$325K Buy
587
+227
+63% +$130K 0.08% 225
2024
Q1 		$209K Sell
360
-71
-16% -$39.8K 0.05% 262
2023
Q4 		$229K Sell
431
-203
-32% -$98.3K 0.05% 265
2023
Q3 		$321K Buy
634
+147
+30% +$78.3K 0.08% 229
2023
Q2 		$254K Buy
487
+60
+14% +$32.4K 0.06% 264
2023
Q1 		$246K Buy
+427
New +$241K 0.07% 237

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Consolidated Portfolio Review Corp's TMO Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Thermo Fisher Scientific (TMO) in Q4 2025, closing a stake of 753 shares — an estimated $365K sold.

Consolidated Portfolio Review Corp first reported a position in TMO in Q1 2023 and held it in 11 quarters. The position peaked at $381K in Q3 2024. 2,710 funds tracked by Wall St. Rank hold TMO as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Thermo Fisher Scientific position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 753 Thermo Fisher Scientific shares in Q4 2025, an estimated $365K.
  • Consolidated Portfolio Review Corp first reported a position in Thermo Fisher Scientific in Q1 2023 and held it in 11 quarters.
  • Consolidated Portfolio Review Corp's Thermo Fisher Scientific position peaked at $381K in Q3 2024.
  • 2,710 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.